- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Viridian Therapeutics Inc (1S1)Viridian Therapeutics Inc stock price live, this page displays NASDAQ VRDN stock exchange data. View the VRDN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Viridian Therapeutics Inc real time stock price chart below.
What Is the Viridian Therapeutics Inc Stock Price Today?
The Viridian Therapeutics Inc stock price today is 19.900.
What Is the Stock Symbol for Viridian Therapeutics Inc?
The stock symbol for Viridian Therapeutics Inc is "VRDN."
What Stock Exchange Does Viridian Therapeutics Inc Trade On?
Viridian Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Viridian Therapeutics Inc a Good Stock to Buy?
Determining whether Viridian Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VRDN quote. (ISIN: US92790C1045)
What Is the Viridian Therapeutics Inc Stock Price Today?
The Viridian Therapeutics Inc stock price today is 19.900.
What Is the Stock Symbol for Viridian Therapeutics Inc?
The stock symbol for Viridian Therapeutics Inc is "VRDN."
What Stock Exchange Does Viridian Therapeutics Inc Trade On?
Viridian Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Viridian Therapeutics Inc a Good Stock to Buy?
Determining whether Viridian Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VRDN quote. (ISIN: US92790C1045)
19.900
-0.500(-2.45%)
Delayed Data
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
19.900
19.900
52 wk Range
10.500
23.400
1S1 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
19.90019.900
52 wk Range
10.50023.400
Key Statistics
Edit
Fair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
Unlock1S1 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
40.620
Upside
+88.492%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
6 analysts have revised their earnings downwards for the upcoming period
- Signal Genetics receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Signal Genetics receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Signal Genetics receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Signal Genetics receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Signal Genetics receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Viridian Therapeutics Inc Company Profile
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company’s product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Compare 1S1 to Peers and Sector
Metrics to compare | 1S1 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship1S1PeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.6x | −3.5x | −0.7x | |
PEG Ratio | −0.40 | −0.09 | 0.00 | |
Price/Book | 3.3x | 1.5x | 2.6x | |
Price / LTM Sales | 5,652.4x | 4.4x | 3.2x | |
Upside (Analyst Target) | - | 257.0% | 44.5% | |
Fair Value Upside | Unlock | 19.4% | 6.6% | Unlock |
People Also Watch
FAQ
What Is the Viridian Therapeutics (1S1) Stock Price Today?
The Viridian Therapeutics stock price today is 19.90
What Stock Exchange Does Viridian Therapeutics Trade On?
Viridian Therapeutics is listed and trades on the Frankfurt stock exchange.
What Is the Stock Symbol for Viridian Therapeutics?
The stock symbol for Viridian Therapeutics is "1S1."
What Is the Viridian Therapeutics Market Cap?
As of today, Viridian Therapeutics market cap is 1.61B.
What is Viridian Therapeutics Earnings Per Share?
The Viridian Therapeutics EPS is -4.26.
From a Technical Analysis Perspective, Is 1S1 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.